TickerTalks
Browse all tickers →
TickerTalks›$MNOV
MNMNOV

MediciNova, Inc.

$MNOV·$124M·Biotechnology·Healthcare
$3.48+37.9%YTD+89.5%1Y+101.6%
Price updated 3m ago
MNMNOV
$MNOVMediciNova, Inc.
$3.48+37.90%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $MNOV on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $MNOV — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventAcceleratingAI verdict · as of 2026-09-17

The move is getting stronger, with heavier trading behind it.

MediciNova at $2.52 — 89% YTD, MN-166 ibudilast ALS SEANOBI Study patient milestone, biotech.

MediciNova is the biopharma franchise (MN-166 ibudilast for ALS/progressive MS) up 89% YTD and 102% over 12 months at $2.52. Q2 revenue was $458K at 69% gross margin — real biotech pre-commercial stage. SEANOBI Study patient enrollment milestone Aug, and Sep 2 material contract termination.

  • Business is pre-commercial: Q2 revenue $458K off Q1's $187K and Q4's $152K — real biotech pre-launch profile with -26.5% ROE and -31.5% ROIC.
  • Structural profile: 0.003 debt/equity signals clean balance sheet at $2.52 — real optionality on MN-166 ibudilast ALS/MS pipeline.
  • Aug SEANOBI Study MN-166 ALS Patient Enrollment Milestone + Aug 19 executive change + Sep 2 material contract termination + Sep investor conferences — coherent catalyst momentum.

Nov 12: EPS above -$0.09 and MN-166 ibudilast / SEANOBI Study commentary keeps acceleration; a trial-setback cools 89%-YTD momentum.

What to watch: The Nov 12 Q3 print — EPS above -$0.09 and MN-166 ibudilast/SEANOBI Study commentary. A trial-setback is what cools 89%-YTD momentum.

On the calendar: 2026-11-12 — Q3 earnings

earnings within 60dbiotech catalystals ms pipeline

Read the AI verdict on $MNOV

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $MNOV.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

Top industry ETF

$IBBiShares Biotechnology ETF
+19.3%YTD
+43.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-31.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-12.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-15.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
134.8Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-26.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
42.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 13, 2026$-0.05$-0.06+21.0%
Q1 2026May 15, 2026$-0.05$-0.06+16.7%
Q4 2025Feb 20, 2026$-0.06$-0.10+36.8%
Q3 2025Nov 13, 2025$-0.06$-0.08+25.0%
Next earningsThu, Nov 12·consensus EPS $-0.06

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$458K+240.6%69.3%-554%$-0.05$-1.9B
Q1 FY26$187K—6.8%-1517%$-0.05$-3.5M
Q4 FY25$152K—34.1%-2038%$-0.05$-2.0M
Q3 FY25$123K—6.5%-2742%$-0.06$-1.7M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$515K$306K – $724K-$0.26-$0.40 – -$0.121
FY27$1.0M$593K – $1.4M-$0.38-$0.58 – -$0.181
FY28$42.7M$24.2M – $61.2M$0.08-$0.12 – $0.282
FY29$126.1M$74.8M – $177.5M$1.04$0.49 – $1.591
FY30$222.6M$132.0M – $313.1M$1.94$0.91 – $2.961

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.25.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.93%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+72.9%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+74.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 42.3M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today3.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.635-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 3 other (3 awards) in window

See when $MNOV insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KAgreement terminatedSep 28-K — Item 1.02: Agreement terminated
8-KOfficer or director changeAug 198-K — Item 5.02: Officer or director change
8-KShareholder voteJun 248-K — Item 5.07: Shareholder vote
+ 7 other (2 10-Qs · 2 proxys · 1 ARS · 1 PRER14A) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

MediciNova to Participate in Two Investor Conferences in Septemberglobenewswire.com·9d agoMediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimateszacks.com·35d agoMediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patientsglobenewswire.com·64d agoMediciNova CEO Provides Shareholder Updateglobenewswire.com·79d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $MNOV on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport